Horm Metab Res 2023; 55(06): 388-394
DOI: 10.1055/a-2065-0845
Original Article: Endocrine Care

Does the Association of Hashimoto's Thyroiditis with Differentiated Thyroid Cancer Really Have a Protective Role?

Authors

  • Ahmet Numan Demir

    1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Zehra Kara

    1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Cem Sulu

    1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Serhat Uysal

    1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Serdar Sahin

    1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Guldana Zulfaliyeva

    2   Department of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Oznur Aydin Atar

    2   Department of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Nahida Valikhanova

    2   Department of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Tulin Ozturk

    3   Department of Medical Pathology, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Hande Mefkure Ozkaya

    1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
  • Mustafa Sait Gonen

    1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
Preview

Abstract

The study is an investigation of aggressive tumor features, prognosis, and disease-specific mortality rates of differentiated thyroid cancer (DTC) in the presence of concomitant Hashimoto’s Thyroiditis (HT). The data of patients with DTC followed in our tertiary care center between 2000–2022 were analyzed. Variables such as patient age, gender, preoperative serum autoantibody levels, tumor characteristics, and treatment modalities were obtained from medical records. The diagnosis of HT was based either on the presence of a positive result in the pathological examination and/or on antibody positivity. A total of 637 patients [mean±SD age, 44.9±13.5 years; 485 women [76.1%)] were included in the analysis. The overall prevalence of coexistent HT was 22.9% (n=146). The disease-specific mortality associated with DTC was 2.9%. DTC patients with HT compared to those without; have more positive lymphovascular invasion (p<0.001), and lymph node metastases (p<0.001). According to the Kaplan–Meier curves, disease-specific survival rates among DTC patients without HT were significantly higher than patients with HT (log-rank p=0.002). The disease-specific mortality rate was 4.79% in DTC patients with HT, it was 1.43% in those without HT. Hashimoto thyroiditis was not associated with a 10-year recurrence-free survival (p=0.059). Differentiated thyroid cancers with concomitant HT are associated with some aggressive tumor features (such as lymphovascular invasion and nodal metastasis) and lower survival. In staging systems based on tumor risk factors, it may be useful to evaluate the presence of concomitant HT as a prognostic factor.

Supplementary Material



Publikationsverlauf

Eingereicht: 24. November 2022
Eingereicht: 29. März 2023

Angenommen: 29. März 2023

Accepted Manuscript online:
29. März 2023

Artikel online veröffentlicht:
09. Mai 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany